Coustets Mathilde, Ladurantie Caroline, Bellard Elisabeth, Prat Mélissa, Rols Marie-Pierre, Ecochard Vincent, Ferron Gwenaël, Chabot Sophie, Golzio Muriel, Paquereau Laurent
Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, 205 Route de Narbonne, BP64182, 31077, Toulouse, France; Urosphere, Parc Technologique Du Canal, Canal Biotech II, 3 Rue des Satellites, 31400, Toulouse, France.
Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, 205 Route de Narbonne, BP64182, 31077, Toulouse, France.
Biomaterials. 2020 May;241:119908. doi: 10.1016/j.biomaterials.2020.119908. Epub 2020 Feb 22.
The epithelial ovarian cancer is one of the most lethal gynecological malignancy due to its late diagnostic and many relapses observed after first line of treatment. Once diagnose, the most important prognostic factor is the completeness of cytoreductive surgery. To achieve this goal, surgeons have to pinpoint and remove nodules, especially the smallest nodules. Recent advances in fluorescence-guided surgery led us to develop a recombinant lectin as a nanoprobe for the microscopic detection of nodules in the peritoneal cavity of tumor-bearing mice. This lectin has an intrinsic specificity for a carcinoma-associated glycan biomarker, the Thomsen-Friedenreich antigen. In this study, after its labelling by a near infrared dye, we first demonstrated that this nanoprobe allowed indirect detection of nodules already implanted in the peritoneal cavity, through tumor microenvironment targeting. Secondly, in a protocol mimicking the scattering of cells during surgery, we obtained a direct and long-lasting detection of tumor cells in vivo. This lectin as already been described as a nanocontainer able to do targeted delivery of a therapeutic compound to carcinoma cells. Future developments will focus on the combination of the nanoprobe and nanocontainer aspects in an intraperitoneal nanotheranostic approach.
上皮性卵巢癌是最致命的妇科恶性肿瘤之一,因为其诊断较晚且在一线治疗后会出现多次复发。一旦确诊,最重要的预后因素是肿瘤细胞减灭术的彻底性。为实现这一目标,外科医生必须精准定位并切除结节,尤其是最小的结节。荧光引导手术的最新进展促使我们开发一种重组凝集素作为纳米探针,用于在荷瘤小鼠腹腔中微观检测结节。这种凝集素对一种癌相关聚糖生物标志物——桑福德 - 弗里德赖希抗原具有内在特异性。在本研究中,在用近红外染料标记后,我们首先证明这种纳米探针能够通过靶向肿瘤微环境间接检测已植入腹腔的结节。其次,在模拟手术过程中细胞扩散的方案中,我们在体内实现了对肿瘤细胞的直接且持久的检测。这种凝集素已被描述为一种能够将治疗性化合物靶向递送至癌细胞的纳米容器。未来的发展将集中于在腹腔内纳米诊疗方法中结合纳米探针和纳米容器这两个方面。